| Cardiovascular Risk Management |
1 |
1 |
| Cardiac Surgery |
0 |
0.8 |
| Lipids Management |
0 |
0.9 |
| Cardiometabolic Risk Factors |
0 |
0.94 |
| Neutrophils |
0 |
0.98 |
| Coronary Artery Disease (CAD) |
0 |
0.62 |
| Cardiovascular disease |
0 |
0.99 |
| Healthcare and Medical Technology |
0 |
0.33 |
| Gout |
0 |
0.25 |
| Clinical Research |
0 |
0.22 |
| New York |
0 |
0.22 |
| Platelet Count |
0 |
0.22 |
| Acute Coronary Syndrome |
0 |
0.2 |
| Biologic Therapy |
0 |
0.17 |
| Heart |
0 |
0.16 |
| Cerebrovascular Accident |
0 |
0.14 |
| Myocardial Infarction (MI) |
0 |
0.14 |
| Biomarker |
0 |
0.11 |
| Interleukin |
0 |
0.11 |
| Patient Safety |
0 |
0.08 |
| Adhesion |
0 |
0.06 |
| Adverse Effects |
0 |
0.06 |
| Atherosclerosis |
0 |
0.06 |
| Cytokines |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Infarction |
0 |
0.06 |
| Interventional Cardiology |
0 |
0.06 |
| Polypharmacy |
0 |
0.06 |
| Prophylaxis |
0 |
0.06 |
| Surgery |
0 |
0.06 |